Table 3.
Canonical pathways predicted by Ingenuity Pathway Analysis for significant genes differentially expressed in kidney cancer
| Ingenuity canonical pathways | -log (p-value) | z-score | Molecules |
|---|---|---|---|
| Wnt/β-catenin Signaling | 0.271 | 2.530 | CSNK1E,MYC,PPP2R4,TGFBR3,CD44,LEF1,SFRP1,UBC,CCND1,HNF1A,ACVR2A,LRP1 |
| Synaptic Long Term Potentiation | 0.481 | −2.333 | PLCB4,PPP1R1A,PPP1R3C,PPP3R1,PRKAR2A,CACNA1C,PLCL1,PLCD4,PRKCZ,PRKCA |
| NRF2-mediated Oxidative Stress Response | 1.5 | −2.333 | GSTA3,AKR7A2,AKR7A3,GSTM1,GSTM3,NQO2,ABCC2,NQO1,DNAJC19,SOD1,PRKCZ,DNAJC11,AKR1A1,SCARB1,FMO1,GSTA1,AOX1,TXN,PRKCA,EPHX1 |
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 0.512 | −2.324 | PPARA,MAP3K15,APOE,APOM,PPP1R3C,PRKCZ,APOL1,ALB,PPP2R4,CYBA,APOC1,CHUK,APOD,RBP4,PRKCA |
| Sperm Motility | 1.19 | −2.309 | PLA2G16,SLC16A10,PLCB4,PLA2R1,PRKAR2A,PNPLA3,PLCL1,PLA2G12B,PDE1A,PLCD4,PLA2G7,PRKCZ,PRKCA |
| Renin-Angiotensin Signaling | 0.279 | −2.121 | ADCY9,GRB2,REN,PRKAR2A,CCL5,PRKCZ,AGT,PRKCA |
| Nitric Oxide Signaling in the Cardiovascular System | 0.27 | −1.890 | KNG1,CAV1,PRKAR2A,CACNA1C,PDE1A,PRKCZ,PRKCA |
| Antioxidant Action of Vitamin C | 3.01 | 1.897 | PLA2G16,NAPEPLD,PLA2R1,SLC23A3,PLA2G7,GLRX,SLC2A3,PLCB4,SLC23A1,SLC2A2,PNPLA3,CHUK,TXN,PLA2G12B,PLCL1,PLCD4 |
| Aldosterone Signaling in Epithelial Cells | 1.34 | −1.897 | DNAJC12,DNAJC19,PDPK1,HSPD1,HSPA2,PRKCZ,HSPA12A,DNAJC11,PLCB4,SCNN1G,SLC12A1,CRYAA/LOC102724652,SCNN1B,PLCL1,PLCD4,PRKCA,AHCY |
| Valine Degradation I | 10.11 | NaN | ECHS1,ABAT,ACADSB,BCKDHB,BCAT1,HIBCH,HIBADH,AUH,DLD,DBT,EHHADH,HADHA,ALDH6A1 |
| Ethanol Degradation II | 9.4 | NaN | HSD17B10,ADH6,ALDH1B1,ALDH4A1,ACSS1,ALDH9A1,ADH5,ALDH2,AKR1A1,ALDH3A2,ACSS2,ADHFE1,ACSL1,ALDH7A1,DHRS4 |
| Fatty Acid β-oxidation I | 9.4 | NaN | HSD17B10,ECHS1,SLC27A2,ACAA1,ACAA2,SCP2,ECI2,AUH,ACSL4,IVD,EHHADH,ACADM,HADHA,ACSL1,HADH |
| FXR/RXR Activation | 9.17 | NaN | PPARA,KNG1,APOE,PKLR,APOH,ABCC2,SLC22A7,HNF1A,CYP8B1,MTTP,PCK2,SCARB1,SLC10A2,FGFR4,LPL,GC,AGT,APOM,SDC1,UGT2B4,CYP27A1,SERPINF2,APOL1,ALB,FABP6,APOC1,FBP1,G6PC,SLC51B,RBP4,APOD |
| Serotonin Degradation | 8.46 | NaN | ADH6,HSD17B10,ALDH4A1,ALDH1B1,UGT3A1,UGT2B4,UGT2B7,UGT1A1,ALDH9A1,ADH5,ALDH2,AKR1A1,SMOX,ALDH3A2,ADHFE1,DHRS4,ALDH7A1,MAOA |
| Noradrenaline and Adrenaline Degradation | 7.86 | NaN | ADH6,HSD17B10,ALDH4A1,ALDH1B1,ALDH9A1,ADH5,ALDH2,AKR1A1,SMOX,ALDH3A2,ADHFE1,DHRS4,ALDH7A1,MAOA |
| Tryptophan Degradation | 7.34 | NaN | ALDH4A1,ALDH1B1,ALDH2,AKR1A1,SMOX,ALDH3A2,DDC,ALDH9A1,ALDH7A1,MAOA |
| PXR/RXR Activation | 4.04 | NaN | PPARA,SCD,GSTM1,ABCB1,ABCC2,PRKAR2A,CES2,HMGCS2,UGT1A1,PCK2,ALDH3A2,GSTA1,G6PC,CYP2B6 |
| Acute Myeloid Leukemia Signaling | 0.491 | 0.816 | RUNX1,MYC,GRB2,LEF1,CCND1,HNF1A,IDH1 |
| Non-Small Cell Lung Cancer Signaling | 0.481 | −0.816 | GRB2,PDPK1,EGF,ERBB2,CCND1,PRKCA |
| PTEN Signaling | 0.662 | 0.905 | FGFR3,GRB2,FGFR4,TGFBR3,PREX2,ITGA5,FGFR2,PDPK1,CHUK,CCND1,PRKCZ |
| Regulation of Cellular Mechanics by Calpain Protease | 0.453 | −1.000 | GRB2,ITGA5,EGF,CCND1,ACTN1 |
| ErbB2-ErbB3 Signaling | 0.967 | −1.890 | MYC,GRB2,NRG3,PDPK1,ERBB3,ERBB2,CCND1 |
| Aryl Hydrocarbon Receptor Signaling | 2.07 | NaN | GSTA3,GSTM1,ALDH4A1,ALDH1B1,GSTM3,NQO2,NQO1,ALDH8A1,CCND1,ALDH9A1,MYC,ALDH1L1,ALDH1L2,ALDH3A2,GSTA1,ALDH5A1,ALDH6A1,ALDH7A1 |
| HER-2 Signaling in Breast Cancer | 1.01 | NaN | GRB2,PARD6B,EGF,ERBB3,ITGB8,ERBB2,CCND1,PRKCZ,PRKCA |
| Thyroid Cancer Signaling | 0.828 | NaN | CXCL10,MYC,LEF1,CCND1,HNF1A |
| Endometrial Cancer Signaling | 0.765 | NaN | MYC,GRB2,PDPK1,LEF1,ERBB2,CCND1 |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 0.615 | NaN | CXCL8,FN1,IL1RL1,CXCL12,CCL5,HNF1A,CCND1,FCGR1A,PRKCZ,C5,MYC,PLCB4,F2RL1,PPP3R1,LEF1,CHUK,SFRP1,PLCL1,PLCD4,FCGR3A/FCGR3B,TNFSF13B,LRP1,PRKCA,ADAMTS4 |
| Estrogen-mediated S-phase Entry | 0.278 | NaN | MYC,CCND1 |
*bold data shows presence and importance of CCND1 among identified canonical pathways